Cargando…

Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options

For the majority of patients with lower-risk myelodysplastic syndrome (LR-MDS), one of the primary clinical goals is to alleviate the symptoms associated with the resultant cytopenias and to minimize the transfusion burden. While supportive red blood cell (RBC) transfusions and erythropoiesis-stimul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lewis, Russell, Bewersdorf, Jan Philipp, Zeidan, Amer M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846829/ https://www.ncbi.nlm.nih.gov/pubmed/33531837 http://dx.doi.org/10.2147/CMAR.S240600

Ejemplares similares

Emerging treatment options for patients with high-risk myelodysplastic syndrome
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2020)

Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis
por: Stahl, Maximilian, et al.
Publicado: (2020)

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2019)

Epigenetic therapy combinations in acute myeloid leukemia: what are the options?
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2019)

Polo-like kinase inhibition as a therapeutic target in acute myeloid leukemia
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

Lower‐risk myelodysplastic syndromes: Current treatment options for anemia
por: Meunier, Mathieu, et al.
Publicado: (2022)

Risk stratification in therapy-related myelodysplastic syndromes
por: Zeidan, Amer M.
Publicado: (2017)

Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes
por: Abou Zahr, Abdallah, et al.
Publicado: (2014)

Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2020)

Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Abaza, Yasmin, et al.
Publicado: (2022)

How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms
por: Gurnari, Carmelo, et al.
Publicado: (2022)

BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?
por: Allen, Cecily, et al.
Publicado: (2021)

P741: PATIENTS’ PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
por: Zeidan, Amer M., et al.
Publicado: (2023)

Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach
por: Awada, Hussein, et al.
Publicado: (2023)

Update on the management of restless legs syndrome: existing and emerging treatment options
por: Facheris, Maurizio F, et al.
Publicado: (2010)

An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma
por: Davis, Alexander, et al.
Publicado: (2022)

Megaloblastic Anemia with Ring Sideroblasts is not Always Myelodysplastic Syndrome
por: Narang, Neha Chopra, et al.
Publicado: (2016)

Pernicious anemia: a myelodysplastic syndrome look-alike
por: Kesbeh, Yazeed, et al.
Publicado: (2019)

More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes
por: Shallis, Rory M., et al.
Publicado: (2018)

Plasma proteome changes associated with refractory anemia and refractory anemia with ringed sideroblasts in patients with myelodysplastic syndrome
por: Májek, Pavel, et al.
Publicado: (2013)

Emerging Therapeutic Options for the Management of COPD
por: Reid, Debra J., et al.
Publicado: (2013)

Lutetium-177 Dotatate-Induced Hemolytic Anemia and Myelodysplastic Syndrome
por: Alkassis, Samer, et al.
Publicado: (2022)

Emerging Therapies for the Myelodysplastic Syndromes
por: Canaani, Jonathan
Publicado: (2019)

An update of polycystic ovary syndrome: causes and therapeutics options
por: Rababa’h, Abeer M., et al.
Publicado: (2022)

Myelodysplastic Syndromes with Bone Marrow Fibrosis: An Update
por: Jain, Akriti G., et al.
Publicado: (2022)

Myelodysplastic syndrome patient-derived xenografts: from no options to many
por: Côme, Christophe, et al.
Publicado: (2020)

Facing the challenge: Novel treatment options for patients with myelodysplastic syndromes
por: Kubasch, Anne Sophie, et al.
Publicado: (2018)

Emerging Treatment Options for Myelofibrosis: Focus on Anemia
por: Sastow, Dahniel, et al.
Publicado: (2023)

Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease
por: Mohty, Razan, et al.
Publicado: (2022)

P745: MULTI-CENTER PHASE IB TRIAL OF THE HISTONE DEACTYLASE INHIBITOR ENTINOSTAT + PEMBROLIZUMAB IN MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA REFRACTORY TO HYPOMETHYLATING AGENTS
por: Bewersdorf, Jan, et al.
Publicado: (2023)

Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities
por: Stahl, Maximilian, et al.
Publicado: (2016)

Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2020)

An update review of emerging small-molecule therapeutic options for COVID-19
por: Tian, Dengke, et al.
Publicado: (2021)

Circulating exosomal microRNAs in acquired aplastic anemia and myelodysplastic syndromes
por: Giudice, Valentina, et al.
Publicado: (2018)

Comment: In Response to “Megaloblastic Anemia with Ring Sideroblasts is not Always Myelodysplastic Syndrome”
por: Gajendra, Smeeta
Publicado: (2017)

The anemia-independent impact of myelodysplastic syndromes on health-related quality of life
por: Wouters, Hanneke J. C. M., et al.
Publicado: (2021)

The impact of erythroblast enucleation efficiency on the severity of anemia in patients with myelodysplastic syndrome
por: An, Chao, et al.
Publicado: (2023)

Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)
por: Brunner, Andrew M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c4k3a2lt96nvllb2ei3md3fhnk